Singapore markets close in 6 hours 1 minute

Straits Times Index
3,356.89
+18.32(+0.55%)
Nikkei
39,780.58
+149.52(+0.38%)
Hang Seng
17,864.89
+146.28(+0.83%)
FTSE 100
8,166.76
+2.64(+0.03%)
Bitcoin USD
62,928.85
-367.11(-0.58%)
CMC Crypto 200
1,343.63
+41.56(+3.19%)

PCVX Oct 2024 95.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

6.85

0.00

(0.00%)

As of 11:34AM EDT. Market open.

Loading interactive chart…

Simply Wall St.
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen